Truce: Mod­er­na backs down in patent fight with NIH as it touts ear­ly boost­er da­ta against Omi­cron

4 years ago
R&D
Coronavirus

US ships out all re­main­ing sup­plies of the on­ly Covid mAb treat­ment that works against Omi­cron

4 years ago
Coronavirus

It’s be­gin­ning to look a lot like M&A sea­son; Aduhelm runs in­to more re­sis­tance; Eli Lil­ly, Bris­tol My­ers get in ...

4 years ago
Weekly

From pa­tient to ad­vo­cate, Chrysalis Ini­tia­tive founder part­ners up to dri­ve breast can­cer care eq­ui­ty for Black women

4 years ago
Pharma
Marketing

Stressed care­givers could use a boost from phar­ma. Think men­tal health and fi­nan­cial help, sur­vey says

4 years ago
Pharma
Marketing

Pur­due's mul­ti-bil­lion dol­lar set­tle­ment in jeop­ardy af­ter fed­er­al judge toss­es deal; Bio­Marin an­nounces glob­al gene ...

4 years ago
News Briefing

For­mer Im­munomedics CFO Us­ama Ma­lik re­sponds to in­sid­er trad­ing charges af­ter 'my ca­reer and ... rep­u­ta­tion ...

4 years ago
People

Biotech start­up lines up more cash to steer its NASH drug through stormy seas

4 years ago
Financing

Roche's Spark in­vests $575M for new gene ther­a­py cen­ter in cen­tral Philadel­phia as part of Drex­el part­ner­ship

4 years ago
Cell/Gene Tx

Pfiz­er plans to study a third shot for its Covid-19 vac­cine in the youngest kids, push­ing back its time­line far­ther

4 years ago
Coronavirus

Omega Funds goes back to the well with newest $650M fund, tak­ing a 'stage-ag­nos­tic' ap­proach to biotech VC

4 years ago
Financing

Deal­ing Bio­gen an­oth­er blow, EMA rec­om­mends re­ject­ing Aduhelm in three terse para­graphs

4 years ago
FDA+

Amy­lyx takes its ALS pro­gram to Nas­daq, rais­ing the stakes for the biotech's on­ly drug

4 years ago
Financing

Covid-19 roundup: CDC rec­om­mends mR­NA vac­cines over J&J’s due to rare blood clots; EU con­sid­ers deal for ...

4 years ago
Coronavirus

FDA per­ma­nent­ly lifts in-per­son re­quire­ments for dis­pens­ing abor­tion pills

4 years ago
FDA+

No­var­tis di­als up lung can­cer ‘Sound Up’ cam­paign to push back against stig­ma

4 years ago
Pharma
Marketing

Ipsen fronts $136M to bag Gen­fit's once-failed NASH drug, bet­ting on its po­ten­tial in rare liv­er con­di­tion

4 years ago
Deals

Sara Kenkare-Mi­tra leaves Genen­tech for a chance to lead neu­ro R&D; Glax­o­SmithK­line alum jumps to Vi­for Phar­ma with ...

4 years ago
Peer Review

Buoyed by semaglu­tide suc­cess, No­vo Nordisk un­corks plans for $2.58B man­u­fac­tur­ing ex­pan­sion in Den­mark

4 years ago
Manufacturing

Days af­ter buy­out news, Vi­for out­lines plan to of­fload 'non-core' fin­ished drug man­u­fac­tur­ing wing

4 years ago
R&D
Manufacturing

Pfiz­er opens doors at newest gene ther­a­py site in NC as part of $800M push in­to next-gen drugs

4 years ago
Cell/Gene Tx
Manufacturing

Sin­ga­pore to get a new man­u­fac­tur­ing, R&D site to fight help in­fec­tious dis­eases

4 years ago
Manufacturing

Drug­mak­ers seek tweaks to ICH guid­ance on con­tin­u­ous man­u­fac­tur­ing

4 years ago
Manufacturing

Oren­cia ap­proved by FDA for new in­di­ca­tion — graft vs host dis­ease; So­sei and Twist an­nounce an­ti­body dis­cov­ery ...

4 years ago
News Briefing
First page Previous page 607608609610611612613 Next page Last page
A service from the Financial Times